Mail-order pharmacy faces charges from Iowa regulators

Image
PROMO 64J1 Health - Drugs Bottles Pills Perscription iStock - Darwin Brandis
© iStock - Darwin Brandis
(Iowa Capital Dispatch)

Iowa regulators have filed charges against a mail-order Florida pharmacy that has been accused of wrongdoing by at least three other states.

The Iowa Board of Pharmacy has charged CRE8 Pharmacy Group of Coral Springs, Florida, with failing to ensure preparations compounded pursuant to federal legal requirements are prepared in accordance with the standards outlined in federal regulations for both sterile and nonsterile compounds.

The company is also charged with failing to comply with the legal requirement that counseling be provided to every patient for a new or changed prescription prior to dispensing the prescription.

Image
Map of the state of Iowa, showing portions of surrounding states
© iStock - PeterHermesFurian

The board has not disclosed the underlying circumstances that gave rise to the charges.

State and federal records indicate CRE8 Pharmacy Group is headed by company CEO Nancy Dube of Parkland, Florida. Dube did not respond Thursday to calls and emails from the Iowa Capital Dispatch, and company officials said there are no media relations or marketing personnel who could comment on the licensing board’s charges.

CRE8 Pharmacy Group is a mail-order compounding pharmacy, founded in 2016, that provides direct-to-patient medications as well as medications for licensed healthcare providers, in 42 states.

In 2023, the Kansas Board of Pharmacy sanctioned CRE8 for allegedly shipping drugs into Kansas at a time when it had no valid registration to do so. The company was fined $1,320.

In 2025, the Louisiana Board of Pharmacy fined CRE8 $5,640 for dispensing approximately 376 prescriptions of compounded products into Louisiana that failed to meet the minimal standards of acceptable pharmacy practice.

Also in 2025, the Ohio Board of Pharmacy suspended CRE8’s license in that state over allegations it sold compounded drugs to clinics containing unapproved or non-FDA-approved components, including the experimental weight-loss drug Retatrutide. CRE8 later entered into a settlement agreement with the Ohio board in which it agreed to pay a civil penalty of $200,000.

On the company’s website, CRE8 Pharmacy Group claims to be compliant with the specific regulations cited by the Iowa board, adding that it holds non-resident licenses, such as the one issued by Iowa, throughout the United States.